vs
Idexx Laboratories（IDXX）与ADVANCED DRAINAGE SYSTEMS, INC.（WMS）财务数据对比。点击上方公司名可切换其他公司
Idexx Laboratories的季度营收约是ADVANCED DRAINAGE SYSTEMS, INC.的1.6倍（$1.1B vs $693.4M），Idexx Laboratories净利率更高（22.8% vs 13.5%，领先9.3%），Idexx Laboratories同比增速更快（14.3% vs 0.4%），Idexx Laboratories自由现金流更多（$326.3M vs $183.6M），过去两年Idexx Laboratories的营收复合增速更高（6.4% vs 3.0%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
Advanced Drainage Systems（简称ADS）是一家美国企业，主营聚丙烯、聚乙烯管材，塑料渗滤场系统、化粪池及配套配件、雨水调蓄设施、PVC排水构件、管件、水过滤与分离设备的设计、生产及销售，是美国规模最大的高密度聚乙烯管道生产商，总部位于俄亥俄州希利厄德。
IDXX vs WMS — 直观对比
营收规模更大
IDXX
是对方的1.6倍
$693.4M
营收增速更快
IDXX
高出13.9%
0.4%
净利率更高
IDXX
高出9.3%
13.5%
自由现金流更多
IDXX
多$142.8M
$183.6M
两年增速更快
IDXX
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $693.4M |
| 净利润 | $248.2M | $93.6M |
| 毛利率 | 60.3% | 37.4% |
| 营业利润率 | 28.9% | 19.7% |
| 净利率 | 22.8% | 13.5% |
| 营收同比 | 14.3% | 0.4% |
| 净利润同比 | 14.8% | 15.3% |
| 每股收益（稀释后） | $3.09 | $1.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXWMS
| Q4 25 | $1.1B | $693.4M | ||
| Q3 25 | $1.1B | $850.4M | ||
| Q2 25 | $1.1B | $829.9M | ||
| Q1 25 | $998.4M | $615.8M | ||
| Q4 24 | $954.3M | $690.5M | ||
| Q3 24 | $975.5M | $782.6M | ||
| Q2 24 | $1.0B | $815.3M | ||
| Q1 24 | $964.1M | $653.8M |
净利润IDXXWMS
| Q4 25 | $248.2M | $93.6M | ||
| Q3 25 | $274.6M | $156.0M | ||
| Q2 25 | $294.0M | $143.9M | ||
| Q1 25 | $242.7M | $77.2M | ||
| Q4 24 | $216.1M | $81.2M | ||
| Q3 24 | $232.8M | $130.4M | ||
| Q2 24 | $203.3M | $161.4M | ||
| Q1 24 | $235.6M | $94.8M |
毛利率IDXXWMS
| Q4 25 | 60.3% | 37.4% | ||
| Q3 25 | 61.8% | 40.0% | ||
| Q2 25 | 62.6% | 39.8% | ||
| Q1 25 | 62.4% | 36.7% | ||
| Q4 24 | 59.8% | 35.0% | ||
| Q3 24 | 61.1% | 37.6% | ||
| Q2 24 | 61.7% | 40.8% | ||
| Q1 24 | 61.5% | 38.5% |
营业利润率IDXXWMS
| Q4 25 | 28.9% | 19.7% | ||
| Q3 25 | 32.1% | 26.3% | ||
| Q2 25 | 33.6% | 24.8% | ||
| Q1 25 | 31.7% | 19.0% | ||
| Q4 24 | 27.4% | 18.4% | ||
| Q3 24 | 31.2% | 23.9% | ||
| Q2 24 | 26.3% | 27.7% | ||
| Q1 24 | 31.0% | 20.7% |
净利率IDXXWMS
| Q4 25 | 22.8% | 13.5% | ||
| Q3 25 | 24.8% | 18.3% | ||
| Q2 25 | 26.5% | 17.3% | ||
| Q1 25 | 24.3% | 12.5% | ||
| Q4 24 | 22.7% | 11.8% | ||
| Q3 24 | 23.9% | 16.7% | ||
| Q2 24 | 20.3% | 19.8% | ||
| Q1 24 | 24.4% | 14.5% |
每股收益（稀释后）IDXXWMS
| Q4 25 | $3.09 | $1.19 | ||
| Q3 25 | $3.40 | $1.99 | ||
| Q2 25 | $3.63 | $1.84 | ||
| Q1 25 | $2.96 | $0.99 | ||
| Q4 24 | $2.62 | $1.04 | ||
| Q3 24 | $2.80 | $1.67 | ||
| Q2 24 | $2.44 | $2.06 | ||
| Q1 24 | $2.81 | $1.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $1.0B |
| 总债务越低越好 | $450.0M | — |
| 股东权益账面价值 | $1.6B | $1.9B |
| 总资产 | $3.4B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资IDXXWMS
| Q4 25 | $180.1M | $1.0B | ||
| Q3 25 | $208.2M | $812.9M | ||
| Q2 25 | $164.6M | $638.3M | ||
| Q1 25 | $164.0M | $463.3M | ||
| Q4 24 | $288.3M | $488.9M | ||
| Q3 24 | $308.6M | $613.0M | ||
| Q2 24 | $401.6M | $541.6M | ||
| Q1 24 | $397.4M | $490.2M |
总债务IDXXWMS
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.3B |
股东权益IDXXWMS
| Q4 25 | $1.6B | $1.9B | ||
| Q3 25 | $1.6B | $1.8B | ||
| Q2 25 | $1.5B | $1.7B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.6B | $1.4B | ||
| Q2 24 | $1.6B | $1.3B | ||
| Q1 24 | $1.6B | $1.2B |
总资产IDXXWMS
| Q4 25 | $3.4B | $4.1B | ||
| Q3 25 | $3.4B | $4.1B | ||
| Q2 25 | $3.3B | $3.9B | ||
| Q1 25 | $3.2B | $3.7B | ||
| Q4 24 | $3.3B | $3.6B | ||
| Q3 24 | $3.4B | $3.5B | ||
| Q2 24 | $3.4B | $3.4B | ||
| Q1 24 | $3.4B | $3.3B |
负债/权益比IDXXWMS
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.83× | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | $269.3M |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $183.6M |
| 自由现金流率自由现金流/营收 | 29.9% | 26.5% |
| 资本支出强度资本支出/营收 | 2.7% | 12.4% |
| 现金转化率经营现金流/净利润 | 1.43× | 2.88× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $577.1M |
8季度趋势，按日历期对齐
经营现金流IDXXWMS
| Q4 25 | $355.8M | $269.3M | ||
| Q3 25 | $402.3M | $234.9M | ||
| Q2 25 | $185.7M | $275.0M | ||
| Q1 25 | $238.0M | $41.2M | ||
| Q4 24 | $262.0M | $189.9M | ||
| Q3 24 | $220.1M | $166.9M | ||
| Q2 24 | $248.3M | $183.4M | ||
| Q1 24 | $198.6M | $17.7M |
自由现金流IDXXWMS
| Q4 25 | $326.3M | $183.6M | ||
| Q3 25 | $371.2M | $176.4M | ||
| Q2 25 | $151.6M | $222.4M | ||
| Q1 25 | $207.9M | $-5.3M | ||
| Q4 24 | $232.8M | $135.7M | ||
| Q3 24 | $192.0M | $112.4M | ||
| Q2 24 | $215.0M | $125.7M | ||
| Q1 24 | $168.3M | $-29.8M |
自由现金流率IDXXWMS
| Q4 25 | 29.9% | 26.5% | ||
| Q3 25 | 33.6% | 20.7% | ||
| Q2 25 | 13.7% | 26.8% | ||
| Q1 25 | 20.8% | -0.9% | ||
| Q4 24 | 24.4% | 19.7% | ||
| Q3 24 | 19.7% | 14.4% | ||
| Q2 24 | 21.4% | 15.4% | ||
| Q1 24 | 17.5% | -4.6% |
资本支出强度IDXXWMS
| Q4 25 | 2.7% | 12.4% | ||
| Q3 25 | 2.8% | 6.9% | ||
| Q2 25 | 3.1% | 6.3% | ||
| Q1 25 | 3.0% | 7.6% | ||
| Q4 24 | 3.1% | 7.9% | ||
| Q3 24 | 2.9% | 7.0% | ||
| Q2 24 | 3.3% | 7.1% | ||
| Q1 24 | 3.1% | 7.3% |
现金转化率IDXXWMS
| Q4 25 | 1.43× | 2.88× | ||
| Q3 25 | 1.47× | 1.51× | ||
| Q2 25 | 0.63× | 1.91× | ||
| Q1 25 | 0.98× | 0.53× | ||
| Q4 24 | 1.21× | 2.34× | ||
| Q3 24 | 0.95× | 1.28× | ||
| Q2 24 | 1.22× | 1.14× | ||
| Q1 24 | 0.84× | 0.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
WMS
| Reportable Segment Aggregation Before Other Operating Segment | $557.3M | 80% |
| Other | $85.5M | 12% |
| Pipe | $35.5M | 5% |
| Allied Products And Other | $15.0M | 2% |
